Cargando…

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis

BACKGROUND: The CheckMate-649 trial compared nivolumab plus chemotherapy (NC) with chemotherapy alone as first-line treatment for advanced gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) and showed significant benefits to progression-free survival an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Xueqiong, Zhang, Mingming, Li, Na, Zheng, Bin, Liu, Maobai, Song, Xiaobing, Cai, Hongfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201153/ https://www.ncbi.nlm.nih.gov/pubmed/37223263 http://dx.doi.org/10.1177/17588359231171038

Ejemplares similares

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2022)

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2023)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
por: Lin, Daniel, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
por: Shu, Yamin, et al.
Publicado: (2022)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2015)

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
por: Satake, Hironaga, et al.
Publicado: (2022)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
por: Janowitz, Tobias, et al.
Publicado: (2016)

Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study
por: Xiang, Jinyu, et al.
Publicado: (2022)

Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis
por: Yang, Liu, et al.
Publicado: (2022)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
por: Zandirad, Eric, et al.
Publicado: (2022)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
por: Fiteni, Frédéric, et al.
Publicado: (2016)

Robust Anti-tumor Response in a Patient with Metastatic Gastroesophageal Junction Adenocarcinoma on Long-term Maintenance Chemotherapy With Trastuzumab Alone: An Unusual Occurrence
por: Haider, Salman, et al.
Publicado: (2020)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers
por: Goff, Laura W., et al.
Publicado: (2014)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
por: Manfredi, Sylvain, et al.
Publicado: (2022)

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
por: Faron, Matthieu, et al.
Publicado: (2023)

Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
por: Liu, Bo-Wei, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
por: Cho, Jang Ho, et al.
Publicado: (2015)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Li, Guichao, et al.
Publicado: (2013)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
por: Ballhausen, Alexej, et al.
Publicado: (2022)

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
por: Wagner, Anna Dorothea, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m3mf40vctsrbva20k6ce24oiu7